Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$250 Mln
P/E Ratio
--
P/B Ratio
10.71
Industry P/E
--
Debt to Equity
-0.82
ROE
-4.7 %
ROCE
427.61 %
Div. Yield
0 %
Book Value
--
EPS
-1.57
CFO
$-75.01 Mln
EBITDA
$-449.67 Mln
Net Profit
$-458.31 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Foghorn Therapeutics Inc (FHTX)
| -9.96 | 20.74 | 3.66 | -22.59 | -29.73 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Foghorn Therapeutics Inc (FHTX)
| -26.64 | 1.10 | -72.10 | 12.83 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses... its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 500 Technology Square, Cambridge, MA, United States, 02139 Read more
President, CEO & Director
Mr. Adrian H. B. Gottschalk
President, CEO & Director
Mr. Adrian H. B. Gottschalk
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Foghorn Therapeutics Inc (FHTX) stood at $ 284 Mln as on 31-Dec-24
The share price of Foghorn Therapeutics Inc (FHTX) is $4.25 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Foghorn Therapeutics Inc (FHTX) has given a return of -29.73% in the last 3 years.
Foghorn Therapeutics Inc (FHTX) has a market capitalisation of $ 250 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Foghorn Therapeutics Inc (FHTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Foghorn Therapeutics Inc (FHTX) and enter the required number of quantities and click on buy to purchase the shares of Foghorn Therapeutics Inc (FHTX).
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 500 Technology Square, Cambridge, MA, United States, 02139
The CEO & director of Mr. Adrian H. B. Gottschalk. is Foghorn Therapeutics Inc (FHTX), and CFO & Sr. VP is Mr. Adrian H. B. Gottschalk.
There is no promoter pledging in Foghorn Therapeutics Inc (FHTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Foghorn Therapeutics Inc (FHTX) | Ratios |
|---|---|
|
Return on equity(%)
|
141.17
|
|
Operating margin(%)
|
-443.7
|
|
Net Margin(%)
|
-383.24
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Foghorn Therapeutics Inc (FHTX) was $0 Mln.
$-0.14
(
